Key Takeaways: Centanafadine, a first-in-class NDSRI, shows promise for ADHD treatment across varied age groups, with significant symptom improvement in phase 3 trials. The drug demonstrated a favorable safety profile, with common adverse events being decreased appetite, nausea, and headache, and low abuse potential. Recent studies indicate centanafadine's potential in addressing emotional dysregulation and executive function deficits by modulating neurotransmitter levels. The FDA's priority review of centanafadine's NDA marks a significant step towards offering a novel ADHD treatment option, with a decision expected by July 24, 2026.